Research Analysts Issue Forecasts for ChromaDex Co.’s Q2 2024 Earnings (NASDAQ:CDXC)

ChromaDex Co. (NASDAQ:CDXC – Get Rating) – Equities researchers at HC Wainwright issued their Q2 2024 earnings per share (EPS) estimates for shares of ChromaDex in a research report issued on Monday, March 13th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.01) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for ChromaDex’s current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for ChromaDex’s Q3 2024 earnings at $0.01 EPS and FY2024 earnings at ($0.03) EPS.

ChromaDex Stock Performance

ChromaDex stock opened at $1.65 on Tuesday. The stock has a 50-day moving average of $1.84 and a two-hundred day moving average of $1.64. ChromaDex has a one year low of $1.15 and a one year high of $2.99. The stock has a market cap of $123.49 million, a PE ratio of -7.17 and a beta of 1.86.

ChromaDex (NASDAQ:CDXC – Get Rating) last issued its quarterly earnings data on Wednesday, March 8th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $21.08 million. ChromaDex had a negative return on equity of 77.39% and a negative net margin of 22.96%. During the same period in the prior year, the business posted ($0.08) EPS.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in ChromaDex by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 558,849 shares of the company’s stock valued at $938,000 after purchasing an additional 5,524 shares during the period. Cambridge Investment Research Advisors Inc. grew its holdings in ChromaDex by 5.9% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 126,558 shares of the company’s stock valued at $213,000 after purchasing an additional 7,000 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in ChromaDex by 74.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,300 shares of the company’s stock valued at $66,000 after purchasing an additional 16,800 shares during the period. International Assets Investment Management LLC acquired a new stake in ChromaDex in the fourth quarter valued at approximately $34,000. Finally, Oppenheimer & Co. Inc. grew its holdings in ChromaDex by 127.3% in the second quarter. Oppenheimer & Co. Inc. now owns 39,110 shares of the company’s stock valued at $65,000 after purchasing an additional 21,900 shares during the period. 42.81% of the stock is currently owned by hedge funds and other institutional investors.

ChromaDex Company Profile

(Get Rating)

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.